Removal Of Aggregate From An IgG4 Product Using CHT™ Ceramic Hydroxyapatite

April 1, 2008

The presence of even trace amounts of aggregate in immunoglobulin biopharmaceuticals is of significant concern during all phases of drug development, from process design to quality control. The formation of aggregates can adversely impact process economics by causing decreased product yield, peak broadening and loss of activity.